Apalutamide for treating high-risk, localised or locally advanced prostate cancer

Apalutamide in combination with androgen deprivation therapy (ADT) is in clinical development for patients with high-risk, localised or locally advanced prostate cancer who are candidates for radical prostatectomy. Prostate cancer is a cancer of the prostate gland (a small organ in a man’s pelvis) and is the most common cancer in older men. Locally advanced prostate cancer is cancer that has started to break out of the prostate or has spread to the area just outside the prostate. ADT uses medicines to reduce testosterone levels and treat prostate cancer. Despite significant advances in treatment options for prostate cancer management, the outcome in some patients is still poor. There is therefore need for more therapy options with significant survival benefits.